Lowenstein represented Cancer Genetics, Inc. (Nasdaq: CGIX) in its recently announced definitive merger agreement with StemoniX, Inc.
Cancer Genetics is a leader in drug discovery and preclinical oncology and immuno-oncology services. StemoniX, a private company, is a leader in developing high-throughput, disease-specific human organoid platforms integrated with leading-edge data science technologies. Under the terms of the merger agreement, StemoniX will merge with a newly formed subsidiary of Cancer Genetics in an all-equity transaction. Upon shareholder approval, the combined company expects to remain listed on the Nasdaq Stock Market. StemoniX will retain its name and become a wholly-owned subsidiary of Cancer Genetics.
The transaction will position the combined company to harness the synergies between two critical modalities of drug discovery and development‒advanced animal models and relevant human high-throughput organoid platforms. The resulting integration of scientific and technology-based expertise, skilled management teams, and ability to offer customers an end-to-end platform will de-risk and accelerate development of preclinical and clinical pipelines for biopharma partners as well as for the proprietary pipeline of the combined company. In combination, Cancer Genetics and StemoniX currently enjoy partnerships and R&D relationships with dozens of global pharmaceutical and biotechnology companies.
Lowenstein has represented Cancer Genetics in numerous transactions since 2011, including in 2019 when Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) acquired its biopharma services business for approximately $23.5 million.
H.C. Wainwright & Co. is acting as financial advisors to the Board of Directors of Cancer Genetics. The Lowenstein deal team includes Alan Wovsaniker, Sam E. Khan, Robert J. Paradiso, Brian A. Silikovitz, Megan Monson, Alexander Dinur, Mitchell McDonald, Erica Perlmutter, and Madeline Roe.
